公开(公告)号：US12098209B2

公开(公告)日：2024-09-24

申请号：US17285367

申请日：2019-10-18

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Ki Joon Cho ,  Mijung Lee ,  Eun Jung Song ,  Ki Su Kim ,  Kwan Yub Kang ,  Eui Cheol Cho

IPC: C07K16/28 ,  A61K38/46 ,  A61K39/00 ,  C12N9/16

CPC classification number: C07K16/2869 ,  A61K38/465 ,  C12N9/16 ,  C12Y301/06013 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.